• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Open-access database of literature derived drug-related Torsade de Pointes cases.文献来源致尖端扭转型室速的药物相关病例的开放获取数据库。
BMC Pharmacol Toxicol. 2022 Jan 10;23(1):7. doi: 10.1186/s40360-021-00548-0.
2
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.多种药物的临床前心脏电生理学、临床QT间期延长与尖端扭转型室速之间的关系:药物研发中临时安全边际的证据
Cardiovasc Res. 2003 Apr 1;58(1):32-45. doi: 10.1016/s0008-6363(02)00846-5.
3
QT prolongation and safety in the Indian population.印度人群中的QT间期延长与安全性
Curr Drug Saf. 2007 Sep;2(3):200-3. doi: 10.2174/157488607781668873.
4
A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).一种新的生物标志物——心脏电生理平衡指数(iCEB)——在药物诱发的心律失常中发挥着重要作用:超越QT间期延长和尖端扭转型室性心动过速(TdP)。
J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):250-259. doi: 10.1016/j.vascn.2013.01.003. Epub 2013 Jan 19.
5
Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.药物性尖端扭转型室性心动过速病例:对欧洲药物警戒数据库中比利时病例的综述
Acta Clin Belg. 2017 Dec;72(6):385-390. doi: 10.1080/17843286.2017.1300217. Epub 2017 Mar 24.
6
Revisiting the hERG safety margin after 20 years of routine hERG screening.重温 20 年常规 hERG 筛选后的 hERG 安全性裕度。
J Pharmacol Toxicol Methods. 2020 Sep;105:106900. doi: 10.1016/j.vascn.2020.106900. Epub 2020 Aug 5.
7
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.与芳香化酶抑制剂相比,他莫昔芬的长QT间期和尖端扭转型室速报告有所增加。
Heart. 2018 Nov;104(22):1859-1863. doi: 10.1136/heartjnl-2017-312934. Epub 2018 May 2.
8
Drug-induced QT Interval Prolongation in the Intensive Care Unit.重症监护病房中的药物性QT间期延长
Curr Clin Pharmacol. 2017;12(4):210-222. doi: 10.2174/1574884713666180223123947.
9
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.抗精神病药物相关的QTc间期延长、尖端扭转型室速和猝死。
Drugs. 2002;62(11):1649-71. doi: 10.2165/00003495-200262110-00006.
10
Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.抗精神病药和抗抑郁药的致心律失常风险:老年人的影响。
Drugs Aging. 2009;26(12):997-1012. doi: 10.2165/11318880-000000000-00000.

引用本文的文献

1
Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.致命性尖端扭转型室速中具有临床意义的药物相互作用的检测:对美国食品药品监督管理局不良事件报告系统的不成比例分析
J Med Internet Res. 2025 Mar 25;27:e65872. doi: 10.2196/65872.
2
Dataset of in vitro measured chemicals neurotoxicity.体外测量的化学物质神经毒性数据集。
Data Brief. 2024 Apr 2;54:110380. doi: 10.1016/j.dib.2024.110380. eCollection 2024 Jun.
3
Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.药物性尖端扭转型室性心动过速:美国食品药品监督管理局不良事件报告系统的不成比例分析
Front Cardiovasc Med. 2022 Oct 24;9:966331. doi: 10.3389/fcvm.2022.966331. eCollection 2022.
4
Correction to: Open-access database of literature derived drug-related Torsade de Pointes cases.对《文献衍生的药物相关性尖端扭转型室速病例开放获取数据库》的更正
BMC Pharmacol Toxicol. 2022 Jan 31;23(1):11. doi: 10.1186/s40360-022-00550-0.

本文引用的文献

1
Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management.用于加强心脏毒性管理的药物诱导性QT间期延长图谱(DIQTA)。
Drug Discov Today. 2022 Mar;27(3):831-837. doi: 10.1016/j.drudis.2021.10.009. Epub 2021 Oct 27.
2
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.羟氯喹、氯喹和阿奇霉素对成人原代心肌细胞的心脏毒性作用。
Toxicol Sci. 2021 Apr 12;180(2):356-368. doi: 10.1093/toxsci/kfaa194.
3
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.药物性心律失常:美国心脏协会的科学声明。
Circulation. 2020 Oct 13;142(15):e214-e233. doi: 10.1161/CIR.0000000000000905. Epub 2020 Sep 15.
4
Trends in clinical success rates and therapeutic focus.临床成功率及治疗重点的趋势
Nat Rev Drug Discov. 2019 Jul;18(7):495-496. doi: 10.1038/d41573-019-00074-z.
5
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.SwissADME:一个免费的网络工具,用于评估小分子的药代动力学、类药性和药物化学友善性。
Sci Rep. 2017 Mar 3;7:42717. doi: 10.1038/srep42717.
6
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.体外全面致心律失常试验(CiPA)计划——进展更新
J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:15-20. doi: 10.1016/j.vascn.2016.06.002. Epub 2016 Jun 7.
7
Evolution of strategies to improve preclinical cardiac safety testing.改善临床前心脏安全性测试策略的演变。
Nat Rev Drug Discov. 2016 Jul;15(7):457-71. doi: 10.1038/nrd.2015.34. Epub 2016 Feb 19.
8
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.通过全面体外致心律失常试验范式看心脏安全性测试领域的新视角。
J Biomol Screen. 2016 Jan;21(1):1-11. doi: 10.1177/1087057115594589. Epub 2015 Jul 13.
9
Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition.Tox-database.net:一个精心整理的资源,用于描述化学物质引发的体外心脏离子通道抑制的数据。
BMC Pharmacol Toxicol. 2012 Aug 13;13:6. doi: 10.1186/2050-6511-13-6.
10
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?我们如何提高对心血管安全性负债的认识,从而开发更安全的药物?
Br J Pharmacol. 2011 Jun;163(4):675-93. doi: 10.1111/j.1476-5381.2011.01255.x.

文献来源致尖端扭转型室速的药物相关病例的开放获取数据库。

Open-access database of literature derived drug-related Torsade de Pointes cases.

机构信息

Pharmacoepidemiology and Farmacoeconomics Unit, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, str., 30-688, Krakow, Poland.

Certara UK Ltd. (Simcyp Division), 1 Concourse Way, Sheffield, S1 2BJ, UK.

出版信息

BMC Pharmacol Toxicol. 2022 Jan 10;23(1):7. doi: 10.1186/s40360-021-00548-0.

DOI:10.1186/s40360-021-00548-0
PMID:35012678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8750847/
Abstract

Since an introduction of an ICH guidance in 2005, no new drugs were withdrawn from the market because of the causation of Torsade de Pointes (TdP). However, the risk of TdP is still a concern for marketed drugs. TdP is a type of polymorphic ventricular tachycardia which may lead to sudden cardiac death. QT/QTc interval prolongation is considered a sensitive, but not specific biomarker. To improve the effectiveness of studies' workflow related to TdP risk prediction we created an extensive, structured, open-access database of drug-related TdP cases. PubMed, Google Scholar bibliographic databases, and the Internet, via the Google search engine, were searched to identify eligible reports. A total of 424 papers with a description of 634 case reports and observational studies were included. Each paper was manually examined and listed with up to 53 variables related to patient/population characteristics, general health parameters, used drugs, laboratory measurements, ECG results, clinical management, and its outcomes, as well as suspected drug's properties and its FDA adverse reaction reports. The presented database may be considered as an extension of the recently developed and published database of drug cardiac safety-related information, part of the tox-portal project providing resources for cardiac toxicity assessment.

摘要

自 2005 年引入 ICH 指南以来,没有新的药物因导致尖端扭转型室性心动过速(TdP)而从市场上撤出。然而,TdP 的风险仍然是上市药物关注的问题。TdP 是一种多形性室性心动过速,可能导致心源性猝死。QT/QTc 间期延长被认为是一种敏感但非特异性的生物标志物。为了提高与 TdP 风险预测相关的研究工作流程的有效性,我们创建了一个广泛的、结构化的、开放获取的药物相关 TdP 病例数据库。通过 PubMed、Google Scholar 书目数据库和互联网上的 Google 搜索引擎,对合格报告进行了搜索。共纳入了 424 篇论文,其中描述了 634 例病例报告和观察性研究。对每篇论文进行了手动检查,并列出了多达 53 个与患者/人群特征、一般健康参数、使用药物、实验室测量、心电图结果、临床管理及其结果以及可疑药物特性和 FDA 不良反应报告相关的变量。所呈现的数据库可被视为最近开发和发布的药物心脏安全性相关信息数据库的扩展,该数据库是 tox-portal 项目的一部分,为心脏毒性评估提供资源。